Abstract:<h2 class="section-title u-h3 u-margin-l-top u-margin-xs-bottom">Abstarct</h2>By removing 5-methyl and 6-acetyl groups in our previously reported compound 3, we designed a series of novel 2,7-diaryl-[1,2,4]triazolo[1,5-a]pyrimidine derivatives as potential tubulin polymerization inhibitors. Among them, compound 5e displayed low nanomolar antiproliferative efficacy on HeLa cells which was 166-fold higher than the lead analogue 3. Interestingly, 5e displayed significant selectivity in inhibiting cancer cells over HEK-293 (normal human embryonic kidney cells). In addition, 5e dose-dependently arrested HeLa in G2/M phase through the alterations of the expression levels of p-cdc2 and cyclin B1, and caused HeLa cells apoptosis by regulation of expressions of cleaved PARP. Further evidence demonstrated that 5e effectively inhibited tubulin polymerization and was 3-fold more powerful than positive control CA-4. Moreover, molecular docking analysis indicated that 5e overlapped well with CA-4 in the colchicine-binding site. These studies demonstrated that 2,7-diaryl-[1,2,4]triazolo[1,5-a]pyrimidine skeleton might be used as the leading unit to develop novel tubulin polymerization inhibitors as potential anticancer agents.

Discovery of 1,5-Diaryl-1,2,4-triazole Derivatives As Myoferlin Inhibitors and Their Antitumor Effects in Pancreatic Cancer.

Modification and Biological Evaluation of a Series of 1,5-Diaryl-1,2,4-triazole Compounds As Novel Agents Against Pancreatic Cancer Metastasis Through Targeting Myoferlin.

Discovery of a Highly Potent and Selective MYOF Inhibitor with Improved Water Solubility for the Treatment of Gastric Cancer.

A Small Molecule Targeting Myoferlin Exerts Promising Anti-Tumor Effects on Breast Cancer

A Potent and Selective Small Molecule Inhibitor of Myoferlin Attenuates Colorectal Cancer Progression.

Discovery and Characterization of 1H-1,2,3-triazole Derivatives As Novel Prostanoid EP4 Receptor Antagonists for Cancer Immunotherapy.

Synthesis, Molecular Modeling, and Biological Evaluation of 1,2,4-Triazole Derivatives Containing Pyridine As Potential Anti-Tumor Agents

Synthesis and biological evaluation of novel Jiyuan Oridonin A-1,2,3-triazole-azole derivatives as antiproliferative agents.

Design, synthesis and evaluation of antiproliferative and antitubulin activities of 5-methyl-4-aryl-3-(4-arylpiperazine-1-carbonyl)-4<i>H</i>-1,2,4-triazole s

Synthesis and Antitumor Activity of 1,2,4-Triazoles Having 1,4-Benzodioxan Fragment As A Novel Class of Potent Methionine Aminopeptidase Type Ii Inhibitors

Identification of 5-Thiocyanatothiazol-2-amines Disrupting WDR5-MYC Protein-Protein Interactions.

Discovery of Novel 4-Arylisochromenes As Anticancer Agents Inhibiting Tubulin Polymerization.

Discovery of highly potent tubulin polymerization inhibitors: Design, synthesis, and structure-activity relationships of novel 2,7-diaryl-[1,2,4]triazolo[1,5-a]pyrimidines

Design, Synthesis and Bioevaluation of Antitubulin Agents Carrying Diaryl-5,5-Fused-Heterocycle Scaffold

Design, synthesis and evaluation of antiproliferative and antitubulin activities of 5-methyl-4-aryl-3-(4-arylpiperazine-1-carbonyl)-4H-1,2,4-triazoles

Novel Dibenzo[b,d]furan-1H-1,2,4-triazole Derivatives: Synthesis and Antitumor Activity.

Discovery of 2,4-Diarylaminopyrimidine Derivatives Bearing Dithiocarbamate Moiety As Novel FAK Inhibitors with Antitumor and Anti-Angiogenesis Activities.

Discovery of Tetrahydropyrazolopyrazine Derivatives as Potent and Selective MYT1 Inhibitors for the Treatment of Cancer

Synthesis and Biological Evaluation of 1-(Benzofuran-3-yl)-4-(3,4,5-trimethoxyphenyl)-1h-1,2,3-triazole Derivatives As Tubulin Polymerization Inhibitors.

Discovery of Novel Arylamide Derivatives Containing Piperazine Moiety As Inhibitors of Tubulin Polymerisation with Potent Liver Cancer Inhibitory Activity.

Discovery of Novel Indole-1,2,4-triazole Derivatives As Tubulin Polymerization Inhibitors.